Press Release: Novartis radioligand therapy -2-

tumor: a SEER database analysis. Cancer Manag Res. 2018;10:5629-5638.

Published 2018 Nov 13. doi:10.2147/CMAR.S174907Dasari

6. A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, Shih T, Yao JC. Trends in

the Incidence, Prevalence, and Survival Outcomes in Patients With

Neuroendocrine Tumors in the United States. JAMA Oncol. 2017;

doi:10.1001/jamaoncol.2017.0589

7. Frilling A, Åkerström G, Falconi, M, et al. Neuroendocrine

tumor disease: an evolving landscape. Endoc Related Cancer 2012; 19:

R163-815.

8. Lawrence B, Gustafsson BI, et al. The Epidemiology of

Gastroenteropancreatic Neuroendocrine Tumors. Endocrinol Metab Clin N Am.

2011; 40:1--18

9. Novartis. Press Release. Available online:

https://www.novartis.com/news/media-releases/advanced-accelerator-applications-receives-fda-approval-lutathera-treatment-gastroenteropancreatic-neuroendocrine-tumors.

Last accessed September 2023.

10. Lutathera. Full Prescribing Information. 2018. Revised March 2023.

https://www.novartis.com/us-en/sites/novartis_us/files/lutathera.pdf

11. Lutathera. Summary of Product Characteristics (SmPC). 2018. Revised

February 2023.

https://www.ema.europa.eu/en/documents/product-information/lutathera-epar-product-information_en.pdf

12. Jadvar H. Targeted radionuclide therapy: an evolution toward precision

cancer treatment. AJR Am J Roentagenol. 2017;209(2);277-288.

13. Jurcic JG, Wong JYC, Knoc SJ, et al. Targeted radionuclide therapy. In:

Tepper JE, Foote RE, Michalski JM, eds. Gunderson & Tepper's Clinical

Radiation Oncology. 5th ed. Elsevier, Inc. 2021;71(3):209-249

# # #

Novartis Media Relations

E-mail:

media.relations@novartis.c

om

Central North America

Richard Jarvis +41 79 584 2326 Julie Masow +1 862 579 8456

Anja von Treskow +41 79 392 9697 Michael Meo +1 862 274 5414

Anna Schäfers +41 79 801 7267 Marlena Abdinoor +1 617 335 9525

Switzerland

Satoshi Sugimoto +41 79 619 2035

Novartis Investor Relations

Central investor relations

line: +41 61 324 7944

E-mail:

investor.relations@novartis.c

om

Central North America

Samir Shah +41 61 324 7944 Sloan Simpson +1 862 345 4440

Nicole Zinsli-Somm +41 61 324 3809 Parag Mahanti +1 973 876 4912

Isabella Zinck +41 61 324 7188

(END) Dow Jones Newswires

September 25, 2023 01:17 ET (05:17 GMT)